Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Delair Gardi

Interventional Cardiology Detroit, MI Medical Doctor

NPI 1205874302 CMS profile 145669

4160 John R St, Suite 724, Detroit, MI 48201

Open in the dashboard

General payments

$62,782

1,018 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Delair Gardi of Detroit, MI is reported in the CMS Open Payments database as having received $62,782 across 1,018 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,383 174
2024 General $29,741 172
2023 General $6,202 150
2022 General $6,196 131
2021 General $10,820 141
2020 General $2,112 119
2019 General $2,329 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Delair Gardi
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Delair Gardi were reported at $5,383. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Delair Gardi Interventional Cardiology median Middle half National median
2019 $2,329 $1,097 $329–$3,048 $163
2020 $2,112 $473 $161–$1,480 $114
2021 $10,820 $677 $233–$1,827 $132
2022 $6,196 $978 $333–$2,724 $149
2023 $6,202 $1,136 $382–$2,986 $160
2024 $29,741 $1,181 $395–$3,326 $164
2025 $5,383 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lexicon Pharmaceuticals, Inc. $25,153 30 payments
  2. AstraZeneca Pharmaceuticals LP $9,653 57 payments
  3. Avinger Inc. $3,270 34 payments
  4. Esperion Therapeutics, Inc. $3,153 15 payments
  5. Edwards Lifesciences Corporation $2,474 14 payments
  6. Inari Medical, Inc. $2,251 10 payments
  7. Novartis Pharmaceuticals Corporation $1,962 119 payments
  8. Boston Scientific Corporation $1,806 91 payments
  9. Janssen Pharmaceuticals, Inc $1,534 86 payments
  10. Endologix, Inc. $1,285 39 payments
  11. Other $10,240 523 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $22,680 8 payments
  2. Food and Beverage $20,537 975 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,315 11 payments
  4. Travel and Lodging $8,107 20 payments
  5. Education $143 4 payments
Products named General payments · program years 2019–2025
  1. Inpefa $25,106 27 payments
  2. FARXIGA $9,208 38 payments
  3. NEXLETOL $3,153 15 payments
  4. NEXLIZET $2,946 3 payments
  5. PANTHERIS $2,876 12 payments
  6. CT THROMBECTOMY SYSTEM KIT $2,341 13 payments
  7. FLOWTRIEVER CATHETER, S $2,341 13 payments
  8. XARELTO $1,510 85 payments
  9. PASCAL $1,429 8 payments
  10. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,045 6 payments
  11. Other $16,444 887 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 69 drugs

Part D claims

14,364

Median for Cardiology: 2,533

Drug cost

$2,108,421

Median for Cardiology: $485,213

Branded share of claims

31.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 578 $546,026
Entresto Sacubitril/Valsartan Brand 441 $493,779
Xarelto Rivaroxaban Brand 413 $381,369
Farxiga Dapagliflozin Propanediol Brand 156 $153,237
Jardiance Empagliflozin Brand 139 $144,337
Brilinta Ticagrelor Brand 164 $121,864
Repatha Sureclick Evolocumab Brand 54 $52,260
Metoprolol Succinate Generic 1,925 $23,372
Verquvo Vericiguat Brand 25 $18,362
Ranolazine Er Ranolazine Brand 235 $17,739

The 10 drugs with the highest cost, of 69 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 103 billing codes

Paid by Medicare

$323,381

Of which drugs: $1,574

Medicare patients

562

Average age 72

Services billed

4,193

323 women, 239 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 64%
Ischemic heart disease 64%
Arthritis 58%
Diabetes 56%
Chronic kidney disease 43%
COPD 36%
Atrial fibrillation 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 72 288 $1,359

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Inpefa
$25,068 — —
FARXIGA
$925 156 —
LEQVIO
$304 — —
XARELTO
$186 413 —
JARDIANCE
$127 139 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

1,018 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record